HD IL-2, such as aldesleukin, which binds to both the intermediate-affinity IL-2Rβγ receptor and the high-affinity IL-2Rαβγ receptor, has been approved for the treatment of MM in many countries worldwide [58]. The gene discussed is IL2; the disease is Miyoshi myopathy.